Humuline 30/70 Cartridge

Humuline 30/70 Cartridge is a prescription insulin product that contains human insulin produced by recombinant DNA technology. It is supplied in a cartridge format designed for use with compatible insulin pens, allowing subcutaneous administration. The formulation provides a mixture of 30% rapid‑acting and 70% intermediate‑acting insulin, facilitating basal and prandial glucose control in patients with diabetes. It is marketed in the European Union and surrounding markets.

Humuline 30/70 Cartridge is indicated for the management of blood glucose in adults with diabetes mellitus.

- Type 1 diabetes mellitus as part of a basal‑bolus insulin regimen. - Type 2 diabetes mellitus when oral agents and lifestyle measures do not achieve target glycaemia. - Adjunct therapy during periods of increased insulin demand, such as illness or surgery. - Use in combination with rapid‑acting insulin analogues for flexible mealtime coverage. - Pediatric patients with type 1 diabetes when weight‑based dosing is appropriate. - Patients requiring a fixed proportion of rapid and intermediate insulin to simplify dosing schedules.

Adverse reactions to Humuline 30/70 may occur; they are categorized by frequency and clinical significance.

Common: - Mild hypoglycemia, especially if meals are delayed or carbohydrate intake is insufficient. - Injection site reactions such as redness, swelling, or itching. - Lipodystrophy presenting as localized thickening or loss of subcutaneous fat at repeated injection sites. - Weight gain associated with increased insulin dosing.

Serious: - Severe hypoglycemia with neuroglycopenic symptoms (confusion, seizures, loss of consciousness). - Allergic reactions ranging from urticaria to anaphylaxis. - Edema or heart failure exacerbation in susceptible patients. - Hypersensitivity leading to serum sickness–like reaction.

When prescribing or using Humuline 30/70, clinicians and patients should consider several precautionary measures to minimize risk.

- Adjust dose during reduced food intake, increased activity, or illness to avoid hypoglycemia. - Monitor blood glucose frequently when initiating therapy or changing insulin‑to‑carbohydrate ratios. - Use caution in renal or hepatic impairment because insulin clearance may be decreased. - Assess for cardiovascular disease; rapid fluid shifts can worsen heart failure. - Avoid use in patients with known hypersensitivity to human insulin or cartridge components.

Humuline 30/70 may interact with other medications; understanding these interactions helps maintain glycemic control and safety.

Avoid: - Concurrent use of other rapid‑acting insulins or insulin analogues without dose adjustment, which can cause severe hypoglycemia. - Beta‑blockers that mask hypoglycemia symptoms, potentially delaying treatment.

Use with caution: - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase insulin secretion, requiring careful glucose monitoring. - Corticosteroids, thiazide diuretics, or sympathomimetics that raise blood glucose, possibly necessitating higher insulin doses. - Alcohol intake, especially in excess, which can cause unpredictable glucose fluctuations.